Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Inventiva S.A. Sponsored ADR IVA

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
928.35
Revenue
19.63
Net Income
(339.12)
Free Cash Flow
(182.91)
Net Debt
(73.72)
Current Ratio
2.96
Debt/Equity
(6.41)
P/E ratio
0.00
P/S ratio
9.96
P/B ratio
0.00
Past 5Y EPS Growth
(18.31%)
This Y EPS Growth
63.75%
Next Y EPS Growth
(3.84%)
Next 5Y EPS Growth
54.17%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2022 2023 2024 2025
Cash 91.39 29.13 104.49 112.36
Receivables 6.33 9.91 5.92 4.86
Inventory 0.39 0.45 — —
Other 13.98 12.66 10.25 159.37
112.09 52.16 120.67 276.59
2022 2023 2024 2025
Payables 20.40 40.78 35.56 29.44
ST’ Debt 6.16 5.74 6.35 36.55
Other 5.79 7.76 88.73 21.56
32.35 54.29 130.64 87.55
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — — — —
8.97
’24 — — — —
15.93
’23 — 2.07 — —
25.07
’22 — 0.07 — 12.89
19.82
’21 0.27 2.32 — 4.61
10.06
’20 1.04 0.18 — 0.26
6.01
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — (60.99) — —
(118.67)
’24 — (52.06) — —
(92.98)
’23 — (49.32) — —
(88.33)
’22 — (27.31) — (19.90)
(47.34)
’21 (9.38) (14.47) — (31.63)
(56.35)
’20 (3.95) (8.06) — (28.91)
(34.94)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — (61.05) — —
(118.95)
’24 — (52.24) — —
(93.34)
’23 — (49.43) — —
(88.77)
’22 — (27.60) — (19.90)
(47.88)
’21 (9.43) (14.54) — (31.63)
(56.88)
’20 (3.95) (8.06) — (28.91)
(35.28)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — — — —
(2.15)
’24 — — — —
(3.33)
’23 — (1.42) — —
(2.63)
’22 — (0.75) — (0.63)
(1.38)
’21 (0.28) (0.45) — (0.76)
(1.50)
’20 — (0.58) — (0.58)
(1.13)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡ ‡‡‡‡‡ 3.49 2.22 1.53 2.11 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 13.66 6.82 4.75 7.98 — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 113 123 118 77 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.18 0.20 0.14 0.12 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.82 25.07 15.93 8.97 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (57.20) (118.86) (199.00) (400.65) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (288.58%) (474.11%) (1,248.89%) (4,467.77%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (57.18) (119.51) (199.34) (400.67) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.79 2.81 5.62 3.65 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.48 0.55 0.27 0.05 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ (1.38) (2.63) (3.33) (2.15) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.14) (1.95) (1.56) (0.64) ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) (0.01) (0.01) 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.16) (1.96) (1.56) (0.64) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.16 (0.76) (1.93) (0.17) ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 41.45 45.35 59.78 186.80 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.03 12.48 5.68 12.35 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.39 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.24 12.70 8.01 8.59 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡
EV/Sales
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.17) (1.94) (1.05) (0.92) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.34) (88.33) (92.98) (118.67) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.55) (0.44) (0.36) (0.28) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (47.88) (88.77) (93.34) (118.95) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 79.74 (2.13) (9.98) 189.05 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 36.36 40.57 58.79 67.73 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (55.02) 11.44 (45.70) (44.64) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 47.91 (34.67) (115.40) (32.27) — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (42.91%) (121.02%) (195.41%) (194.96%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (74.72%) (1,804.49%) 265.66% 542.65% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Inventiva S.A. (IVA), a clinical-stage biotech targeting fibrosis diseases like MASH, has endured a decade of high R&D burn, clinical delays, and sector headwinds, including post-COVID funding squeezes and FDA hurdles. Despite persistent losses, deepening dilution (shares projected to triple to 191 million by 2027), and negative equity (-$115 million in 2024), its lead asset lanifibranor advances in Phase 3 trials, fueling analyst optimism. Trading at a steep discount—13% below low-end targets, 79% below mean, and 266% below high—IVA’s recent close signals potential undervaluation amid compressed PS ratios (5.7x) and pristine 100% gross margins on partnership revenues.

Revenue volatility defines operations: a 26% rise to $25.1 million in 2023 gave way to a 36% drop to $15.9 million in 2024, with per-employee efficiency sliding 34% to $135K. Forecasts depict a trough—20% decline to $12.8 million in 2025, 73% plunge to $3.4 million in 2026—before a staggering 4,600% surge to $161 million in 2027, tied to commercialization hopes. Profitability lags with EPS worsening 195% to -3.33, FCF at -$93 million, and cash burn per share at -$1.56, though net debt improved to -$46 million.

Analysts project EPS stabilization (-0.65 by 2027) and FCF positivity, with mean targets implying 79% upside hinging on Phase 3 data (~2026) and MASH tailwinds (10-15% prevalence). Risks include cash runway strains necessitating raises amid -$225 million 2025 losses, but easing rates and M&A dry powder could catalyze a rebound, embodying biotech’s high-asymmetry bet.

Read full commentary →

Inventiva S.A. Sponsored ADR (IVA) Latest News

News by impact score

Fine-tune

2 Sep

4 , 4:05 PM
Inventiva completes last patient visit in NATiV3 Phase 3 trial of lanifibranor for MASH. Phase 3 trial completion milestone advances lanifibranor toward data readout and potential approval.

30 Jul

3 , 4:00 PM
Inventiva issues correction to preliminary financial results for first half of 2026. Correction to preliminary financial results can alter investor sentiment regarding the company's financial health.

29 Jul

3 , 4:00 PM
Inventiva announces preliminary financial results for the first half of 2026. Half-year financial results release may moderately affect stock performance and investor views without guaranteed fundamental shifts.

12 Jul

3 , 9:08 AM
Inventiva puts its MASH narrative to the test after a recent rebound. MASH narrative test after rebound may moderately affect IVA market trajectory and sentiment.

16 Jun

4 , 5:12 AM
Claret Capital Partners participates in €130m financing for Inventiva. €130m financing round supplies major capital influx likely to boost Inventiva's development efforts substantially.

4 , 4:52 AM
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development. €130m financing round directly funds Phase 3 trials and materially strengthens Inventiva's development runway.

12 Jun

3 , 4:00 PM
Inventiva repays EIB loans, repurchases portion of EIB warrants and issues first two tranches under new debt financing. Debt restructuring and new financing alter Inventiva capital structure and financial flexibility.

2 Jun

4 GlobeNewswire, 8:29 AM
Inventiva announces debt and equity financing to optimize capital structure ahead of anticipated Phase 3 readout. Debt and equity raise strengthens balance sheet ahead of pivotal Phase 3 milestone.

3 GlobeNewswire, 8:30 AM
Inventiva S.A. resumes trading of ordinary shares on Euronext Paris. Resumption directly restores share liquidity and trading access on Euronext Paris for Inventiva.

21 May

3 Simply Wall St., 2:11 AM
Inventiva faces deepening losses as its MASH trial advances, prompting reassessment of the company's valuation and Sponsored ADR outlook amid ongoing clinical developments. Deepening losses combined with MASH trial progress create moderately noticeable effects on valuation and investor sentiment without fundamentally redefining company trajectory.

22 Apr

4 Exec Edge, 6:03 PM
Inventiva strengthens its leadership team with key hires in preparation for potential commercialization of its pipeline assets. Building leadership for commercialization signals major strategic preparation that could significantly enhance market readiness and investor confidence.

4 GlobeNewswire, 4:00 PM
Inventiva S.A. strengthens leadership team ahead of expected Phase 3 data readout for lanifibranor. Leadership enhancements ahead of pivotal Phase 3 readout prepare for potentially trajectory-altering clinical outcomes.

7 Apr

4 Simply Wall St., 12:32 AM
Inventiva's narrative shifts with advancing Lanifibranor, its lead drug candidate for NASH/MASH, amid positive phase 3 trial momentum and analyst upgrades raising price targets to €12-20, signaling improved commercial prospects despite cash burn concerns. Lanifibranor progress and analyst upgrades represent major strategic advancements for Inventiva's pipeline and valuation.

1 Apr

4 GuruFocus.com, 9:01 PM
Inventiva S.A. (IVA) Q4 2025 earnings call highlights strategic milestones and financial performance, covering key operational advancements and future outlook. Earnings call highlights strategic milestones that could significantly alter IVA's trajectory and investor sentiment.

31 Mar

4 www.marketbeat.com, 10:10 AM
Inventiva S.A. (IVA) Q4 earnings call highlighted financial results, lanifibranor Phase 3 progress in MASH, positive NATiV3 trial data, cash runway into Q3 2025, and 2024 milestones including LEGEND study initiation. Q4 highlights detail significant clinical advancements and financial stability poised to boost investor confidence and stock trajectory.

30 Mar

4 GlobeNewswire, 4:11 PM
Inventiva S.A. Sponsored ADR (IVA) reported full-year 2025 results and provided a business update. Full-year results and business updates reveal financial performance and strategic progress, significantly affecting stock trajectory and investor sentiment.

27 Feb

4 , 9:55 AM
Wall Street analysts expect Inventiva S.A. Sponsored ADR (IVA) to rally 136.34%, highlighting strong upside potential. Analyst consensus targets 136.34% upside for IVA, signaling major positive shift in investor sentiment and market trajectory.

17 Feb

4 GlobeNewswireGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com, 2:30 AM
Inventiva S.A. Sponsored ADR (IVA) reported preliminary financial results for its 2025 fiscal year. Preliminary fiscal year financial results signal key financial health metrics that can substantially sway IVA's stock performance and investor outlook.

14 Feb

4 www.marketbeat.com, 12:02 AM
Inventiva S.A. announced that its Phase 3 Lanifibranor MASH trial has been fully enrolled, with top-line data expected to be released in the second half of the year. This milestone is significant for the company's development of Lanifibranor, a treatment for non-alcoholic steatohepatitis (NASH), as it moves closer to potential market approval. The completion of enrollment in a Phase 3 trial is a critical step that could significantly influence the company's future performance and investor sentiment.

4 Feb

3 GlobeNewswireReuters, 4:00 PM
Inventiva S.A. Sponsored ADR (IVA) will present at the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its ongoing commitment to innovation in the biotech sector. The event will provide a platform for the company to showcase its latest developments and engage with investors and industry experts. Participation in a prominent biotech summit may enhance visibility and investor interest, but the overall impact on long-term performance is expected to be limited.

30 Jan

4 Simply Wall St., 1:11 PM
Inventiva S.A. Sponsored ADR (IVA) has achieved a remarkable 126% total return over the past year, prompting a reassessment of its valuation. The company's performance is attributed to advancements in its clinical pipeline and strategic partnerships, which have bolstered investor confidence. Analysts are now evaluating the sustainability of this growth and its implications for future market positioning. The stock's recent surge has sparked interest among investors, leading to discussions about potential future developments and market dynamics that could influence Inventiva's trajectory. The significant total return and advancements in the clinical pipeline indicate a likely major impact on future performance and investor sentiment.

28 Jan

4 ReutersZacksPharmaceutical TechnologyBioPharma DiveMotley FoolMT NewswiresZacksMotley Fool, 10:57 AM
Inventiva S.A. Sponsored ADR (IVA) experienced a 50% surge in stock price, driven by investor optimism regarding its liver disease drug. The increase reflects positive sentiment surrounding the company's potential to address significant unmet medical needs in liver diseases, particularly non-alcoholic steatohepatitis (NASH). Investors are closely monitoring the drug's development and upcoming clinical trial results, which could further influence the company's market position and financial outlook. The surge in stock price indicates significant investor confidence in the potential impact of the liver disease drug on the company's future performance.

26 Jan

4 ZacksZacksZacksZacksZacksZacksZacksMT Newswires, 12:00 PM
Inventiva S.A. Sponsored ADR (IVA) is highlighted as a strong momentum pick due to its recent performance and growth potential. The company is positioned well within its sector, showing promising developments that could attract investor interest. Analysts suggest that IVA's strategic initiatives and market positioning make it a compelling choice for those seeking momentum stocks. Significant strategic initiatives and market positioning are likely to influence future performance and investor sentiment.

8 Jan

4 Zacks, 9:55 AM
Wall Street analysts forecast a potential upside of 200.59% for Inventiva S.A. Sponsored ADR (IVA), driven by positive developments in the company's pipeline and market positioning. The optimistic outlook is based on recent advancements in their clinical trials and strategic partnerships that could enhance their competitive edge. Investors are encouraged to consider these factors when evaluating IVA's future performance. Significant advancements in clinical trials and strategic partnerships could alter the company's trajectory and investor sentiment.

25 Dec

4 Simply Wall St., 3:06 AM
Recent data and valuation shifts are positively influencing the narrative surrounding Inventiva S.A. Sponsored ADR (IVA). The company is experiencing renewed investor interest due to promising developments in its product pipeline and strategic initiatives. Analysts are adjusting their valuations, reflecting a more optimistic outlook for the company's future performance. This shift is expected to enhance market sentiment and could lead to increased stock performance as Inventiva navigates its upcoming milestones. Positive developments in product pipeline and strategic initiatives are likely to significantly impact future performance and investor sentiment.

18 Dec

4 Insider MonkeySimply Wall St.Simply Wall St.Insider MonkeyInsider MonkeyInsider MonkeyInsider Monkey, 3:16 AM
Wall Street analysts are optimistic about Inventiva S.A. (IVA) due to its promising pipeline of drug candidates, particularly in treating rare diseases. The company's recent clinical trial results have shown positive outcomes, boosting investor confidence. Additionally, strategic partnerships and collaborations are expected to enhance its market position and drive future growth. Analysts highlight the potential for significant revenue generation as the company advances its therapies through regulatory processes. Positive clinical trial results and strategic partnerships are likely to significantly impact future performance and investor sentiment.

17 Dec

3 GlobeNewswire, 4:00 PM
Inventiva S.A. will present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its ongoing commitment to advancing its pipeline and engaging with investors. The conference is a key event for healthcare companies to showcase their innovations and strategies to a broad audience of investors and analysts. Participation in a major healthcare conference can enhance visibility and investor interest, potentially influencing market sentiment.

9 Dec

4 Simply Wall St., 9:12 PM
Inventiva S.A. is experiencing a shift in its valuation narrative ahead of the 2026 Phase 3 readout for its lead drug candidate. The upcoming data is expected to significantly influence investor sentiment and the company's market position. Analysts are closely monitoring the implications of this readout, as it could lead to substantial changes in Inventiva's financial outlook and strategic direction. The anticipation surrounding the results is reframing how stakeholders view the company's potential for growth and profitability in the competitive biopharmaceutical landscape. The 2026 Phase 3 readout is likely to significantly impact Inventiva's future performance and investor sentiment.

28 Nov

3 GlobeNewswire, 2:30 AM
Inventiva S.A. held a Combined Shareholders’ General Meeting on November 27, 2025, where key resolutions were voted on and approved, impacting the company's governance and strategic direction. Shareholders discussed various proposals, including financial reports and future initiatives, reflecting the company's ongoing commitment to transparency and stakeholder engagement. The outcomes of the meeting may influence the company's strategic direction and governance, but the overall effect is expected to be somewhat limited.

25 Nov

4 Simply Wall St., 6:16 PM
Analysts are expressing optimism about Inventiva S.A. Sponsored ADR (IVA) due to promising new data that could enhance the company's growth trajectory. Recent developments in clinical trials and product innovations have garnered positive attention, suggesting potential for improved market performance. Investors are encouraged by the company's strategic direction and the implications of these advancements on future profitability. Positive new data and analyst optimism indicate significant potential for growth and market performance changes.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us